81846-19-7
Chemical Structure
Treprostinil
Synonym(s): UT-15
- CAS No.: 81846-19-7
- Formula:C23H34O5
- Molecular Weight:390.51
IUPAC Name: 2-(((1R,2R,3aS,9aS)-2-hydroxy-1-((S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl)oxy)acetic acid
InChIKey: PAJMKGZZBBTTOY-ZFORQUDYSA-N
SMILES: OC(COC1=CC=CC2=C1C[C@](C[C@@H](O)[C@@H]3CC[C@@H](O)CCCCC)([H])[C@]3([H])C2)=O
Biological Activity: Treprostinil (UT-15) is a potent DP1 and EP2 agonist with EC50 values of 0.6±0.1 and 6.2±1.2 nM, respectively.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Treprostinil | 99.95% | Treprostinil (UT-15) is a potent DP1 and EP2 agonist with EC50 values of 0.6±0.1 and 6.2±1.2 nM, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Treprostinil (Standard) | ≥98% | Treprostinil (Standard) is the analytical standard of Treprostinil. This product is intended for research and analytical applications. Treprostinil (UT-15) is a potent DP1 and EP2 agonist with EC50 values of 0.6±0.1 and 6.2±1.2 nM, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Treprostinil-d7 | Treprostinil-d7 (UT-15-d7) is a deuterated version of Treprostinil (HY-100441). Treprostinil is a highly potent DP1 and EP2 agonist with EC50s of 0.6 nM and 6.2 nM, respectively. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Treprostinil-d9 | 99.79% | Treprostinil-d9 (UT-15-d9) is the deuterium-labeled Treprostinil (HY-100441). Treprostinil (UT-15) is a potent DP1 and EP2 agonist with EC50 values of 0.6±0.1 and 6.2±1.2 nM, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Treprostinil-13C2,d | Treprostinil-13C2,d is the 13C- and deuterium labeled Treprostinil. Treprostinil (UT-15) is a potent DP1 and EP2 agonist with EC50 values of 0.6±0.1 and 6.2±1.2 nM, respectively. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||